Bayer AG
Since our original Bayer analysis in early August, the fundamental picture has remained largely unchanged. At the same time, there have been further developments in the legal situation and in the technical picture.
Rather than recalculating the entire MUMAK model after every market move, this update focuses on the factors that have changed since our previous analysis: legal developments, market sentiment, and chart technicals.
What has changed since our last analysis?
Bayer continues to operate on the basis of the Q2 2026 results, which showed improved operational performance, particularly at Crop Science. At the same time, cash flow, debt levels, and litigation-related payments remain important points of observation.
On the legal side, the next step in the proposed Roundup class settlement has been postponed. The final fairness hearing is now scheduled for September 14, 2026. This gives the parties additional time to process motions for revocation of previously declared opt-outs following the U.S. Supreme Court’s Durnell decision.
At the same time, Bayer’s share price has entered a technical consolidation phase following the sharp rally in June and early July.
Against this backdrop, the key question is whether Bayer can confirm the improved operational and legal positioning while finding a new technical direction after the recent consolidation.
Rating
This analysis assesses Bayer AG under the UMBRELLA strategy using the MUMAK method.
The valuation is conducted across five decision-making phases: Geopolitics, Industry, Fundamentals, Market Sentiment, and Technical Analysis.
The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic.
We explain – you decide.
Geopolitics
Classification
Bayer operates in two strategically important areas: food security and healthcare.
Demand for food, agricultural productivity, and medicines remains central even in times of geopolitical uncertainty. This gives Bayer a relatively defensive global position.
At the same time, regulatory and political decisions remain key drivers. Drug prices, approvals in the agricultural sector, and international trade rules can affect the business.
Overall, Bayer’s exposure to essential industries offers more opportunities than geopolitical risks.
Opportunities
- Food security: Governments are increasingly prioritizing a reliable food supply and higher agricultural productivity.
- Agricultural technology: Farmers need higher yields and more efficient production. This supports demand for seeds and crop protection solutions.
- Essential healthcare: Demand for medicines remains relatively stable even in times of economic or political uncertainty.
- Global presence: Bayer operates in around 80 countries. This reduces dependence on individual markets.
- Greater legal clarity in the US: The US Supreme Court’s decision in the Durnell case improves Bayer’s position against lawsuits alleging inadequate warning labels.
- Growing demand in healthcare: Oncology as well as cardiovascular and kidney diseases offer long-term growth opportunities.
- Diversification: Bayer combines agriculture and healthcare. Both areas serve fundamental global needs.
Risks
- Trade restrictions: Tariffs and trade conflicts can increase costs and disrupt supply chains.
- Geopolitical conflicts: Wars and political tensions can raise energy, logistics, and raw material costs.
- Agricultural conditions: Weather conditions, agricultural prices, and farmers’ income situation can influence demand.
- Drug prices: Governments can put pressure on the prices of pharmaceutical products.
- Regulation: Agricultural products require regulatory approvals in many countries.
- Patent expiries: The loss of exclusivity can increase competition and reduce revenues in the pharma business.
Key takeaway: Bayer benefits from its strong position in food security and healthcare, while the company’s global presence helps offset geopolitical and regulatory risks.
MUMAK.me Rating Phase 1: Positive = 1 MUMAK
Bayer AG
Industry
Assessment
Bayer operates in three major life science markets:
- Crop Science: seeds, crop protection, and agricultural technology
- Pharmaceuticals: prescription medicines
- Consumer Health: over-the-counter health products
Crop Science benefits from better operational execution, lower manufacturing costs, and a stronger seeds and traits business. In Pharmaceuticals, Nubeqa and Kerendia are growing rapidly, while Xarelto and Eylea are declining due to expiring exclusivity and increasing competition. Consumer Health remains stable but faces a weaker consumer environment in the USA.
Valuation Comparison
| Metric | Bayer 2026e | Industry average* | Rating |
|---|---|---|---|
| P/E Ratio | 20.5x | approx. 17-23x | Weaker / Highly valued |
| EBIT Margin | 12,5 % | approx. 17-25% | Weaker |
| Net margin | 4,7 % | approx. 10-18% | Weaker |
| Revenue Growth | approx. 0.4% | approx. 3-7% | Weaker |
*Based on Novartis, Roche, Sanofi, Merck KGaA, Corteva, and other major pharmaceutical and agricultural companies.
Source: MarketScreener, consensus estimates 2026, as of August 24, 2026.
Opportunities
- Global concerns about food security continue to support demand for agricultural innovation.
- Climate change increases the need for resilient seeds and effective crop protection solutions.
- New drugs could increasingly offset declining sales of established medicines.
- Consumer Health provides comparatively defensive and highly predictable demand.
- The combination of healthcare and agriculture gives Bayer a broad alignment with essential long-term demand drivers.
Risks
- Patent expirations in the pharmaceutical business create ongoing pressure to continuously renew the product portfolio.
- Developing new drugs remains cost-intensive, while clinical and regulatory success is not guaranteed.
- Agricultural markets are sensitive to weather conditions, crop prices, and farmer spending.
- Environmental regulations could restrict the use of certain crop protection products.
- Bayer competes with more focused and in some cases more profitable peers.
Key takeaway: Bayer operates in industries supported by attractive long-term demand trends. Its presence in healthcare, agriculture, and consumer health provides broad diversification.
MUMAK.me Assessment Phase 2: Positive = 1 MUMAK
Bayer AG
Fundamentals
Assessment
Bayer’s results for the second quarter were operationally solid. Group sales rose by 2.2% on a currency- and portfolio-adjusted basis to EUR 10.872 billion, while EBITDA before special items increased by 1.9% to EUR 2.144 billion.
Revenue by Business Segment
| Segment | Revenue Q2 2026 | Sales Q2 2025 | Change |
|---|---|---|---|
| Crop Science | EUR 4.910 billion | EUR 4.788 billion | +3,5 % |
| Pharmaceuticals | EUR 4.458 billion | EUR 4.470 billion | +0,8 % |
| Consumer Health | EUR 1.445 billion | EUR 1.427 billion | +1,5 % |
Source: Bayer Half-Year Financial Report Q2 2026.
Within Pharmaceuticals, sales of Nubeqa rose by 63.9% and Kerendia by 82.9% on a currency- and portfolio-adjusted basis. This was offset by significant declines for Xarelto and Eylea. This illustrates the size of the gap created by patent expirations that Bayer still needs to close.
The balance sheet is improving more slowly than the adjusted result. Free cash flow in the second quarter was EUR -371 million and EUR -2.691 billion in the first half, mainly due to payments related to litigation. Net financial debt amounted to EUR 33.647 billion as of June 30.
Financial performance
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | EUR 10.872 billion | EUR 10.739 billion | +1,2 % |
| EBITDA before special items | EUR 2.144 billion | EUR 2.105 billion | +1,9 % |
| Net Income | EUR 0.219 billion | EUR -0.199 billion | Improved |
| EPS | €0.95 | EUR 1.14 | -16,7 % |
| Free cash flow | EUR -0.371 billion | EUR 0.125 billion | Lower |
Source: Bayer Half-Year Financial Report Q2 2026.
Financial Development
Key Observations:
- Sales peaked in 2022 and have fallen for three consecutive years on a reported basis.
- Adjusted EBITDA has also declined since 2022, although the first half of 2026 shows a significant operational recovery.
- Reported net income has been negative since 2023 because litigation costs, impairments, and financing costs overshadow the underlying earning power.
- The dividend remains at the legal minimum level while management prioritizes the balance sheet.
Outlook 2026
Source: MarketScreener consensus, August 5, 2026. Actual figures 2025; estimates 2026-2028.
The consensus forecast assumes a gradual recovery rather than a transformation into a high-growth company.
The forecasts indicate the following:
- Sales will remain largely stable in 2026 before growing again in the low single-digit percentage range.
- Adjusted EBITDA will start to rise again from 2027 as savings and new products gain weight.
- Reported net income is expected to turn positive again in 2026 and improve further through 2028.
Opportunities
- Crop Science achieved significant margin expansion, showing that the productivity program is taking effect.
- Nubeqa and Kerendia are growing fast enough to become significant replacement products for established drugs.
- The U.S. Supreme Court ruling significantly improves Bayer’s legal position in Roundup lawsuits regarding inadequate warning labels.
- Apollo’s EUR 3.0 billion capital contribution opens a credible path to reducing debt by year-end.
Risks
- Free cash flow remains negative as litigation payments consume operational cash flow.
- Net financial debt remains high relative to earnings and market capitalization.
- The declining performance of Xarelto and Eylea continues to weigh on the Pharmaceuticals division.
Key takeaway: Fundamentals are improving, but cash flow and leverage currently prevent an unreservedly positive valuation. Nevertheless, the trend appears to be moving in the right direction.
MUMAK.me Assessment Phase 3: Positive = 1 MUMAK
Bayer AG
News, Analysts, and Market Sentiment
Assessment
Market sentiment toward Bayer remains positive, supported by recent operational results. At the same time, the legal situation remains an important factor. Recent developments have improved the outlook in connection with the Roundup litigation, while litigation-related payments and the ongoing lawsuits represent a material source of uncertainty.
Bayer’s Q2 2026 results provided a solid operational foundation.
In the pharmaceutical business, newer products such as Nubeqa, Kerendia, and Beyonttra are increasingly supporting the transition from established products such as Xarelto and Eylea. Further regulatory progress, including the expanded approval of LYNKUET in Canada, complements the development of Bayer’s pharmaceutical portfolio.
The legal environment has also developed more constructively following the U.S. Supreme Court’s decision in Durnell. The decision strengthened Bayer’s position regarding federal preemption in Roundup lawsuits alleging inadequate warnings. However, the litigation continues to have significant financial impact: in the first half of 2026, litigation-related cash outflows totaled approximately EUR 2.5 billion.
External valuation analyses have also become more constructive recently. An analysis published via Yahoo Finance/Simply Wall St estimated Bayer’s fair value at approximately EUR 54.92, suggesting—based on the assumptions used there—a valuation below the calculated fair value. This provides an additional sentiment indicator, but does not replace MUMAK’s fundamental valuation model.
Analyst Consensus
| Average Recommendation | ACCUMULATE |
| Number of Analysts | 18 |
| Average Price Target | approx. EUR 56.8 |
| Upside to Average Target | +18,3 % |
| Highest price target | EUR 65 |
| Lowest Price Target | EUR 46 |
Source: MarketScreener consensus, August 24, 2026.
The analyst consensus remains positive. The average price target is approximately 18.3% above the reference price used.
Interesting Fact
Apollo Transaction
Bayer agreed with Apollo on an equity injection of EUR 3 billion.
Apollo will acquire a minority stake in a new company into which Bayer will contribute its long-acting contraceptive business. Bayer will retain the majority stake and operational control.
The transaction strengthens the balance sheet without Bayer having to sell the entire business. Closing is expected in the second half of 2026, subject to regulatory approval.
Opportunities
- Improved legal outlook: The Durnell decision strengthens Bayer’s position in the Roundup litigation and could help reduce long-term legal uncertainty.
- Pharma pipeline: Growth from Nubeqa, Kerendia, Beyonttra, and LYNKUET could increasingly offset pressure from declining sales of established products.
- Crop Science performance: Improved profitability in the second quarter supports the group’s operational development.
- Analyst expectations: The current average price target of EUR 56.83 suggests further upside potential relative to the current share price.
Risks
- Ongoing legal risks: The Roundup and PCB proceedings continue to represent a material source of legal and financial uncertainty.
- Cash flow pressure: Litigation-related payments remain high and weighed significantly on free cash flow in the first half of 2026.
- Patent expirations: Declining contributions from established pharmaceutical products, particularly Xarelto and Eylea, must increasingly be offset by newer growth products.
- Execution risks: Bayer must continue to demonstrate sustainable improvement in profitability, cash generation, and debt reduction.
Key takeaway: Market sentiment toward Bayer remains positive, supported by progress in the pharma pipeline and a more constructive legal environment.
MUMAK.me Evaluation Phase 4: Positive = 1 MUMAK
Bayer AG
Technical Analysis
Assessment
The technical picture of Bayer’s share price has weakened in the near term following the sharp uptrend between May and July.
On August 24, 2026, the share was trading at approximately EUR 47.45. After the price had been above EUR 50 in early August, the share has entered a consolidation phase and is currently trading below the recent resistance area.
Performance over recent weeks/months
(as of August 24, 2026)
| Indicator | Rating | Interpretation |
|---|---|---|
| RSI (14) | Neutral | At approximately 48.5, the RSI is near the middle of its range and signals neither an overbought nor an oversold condition. |
| MACD | Negative | The MACD line has fallen below the signal line, indicating weaker near-term momentum. However, both lines remain above the zero line, so the broader recovery has not been fully reversed to date. |
| Bollinger Bands | Neutral | Following the decline from the upper band, the share is trading in the lower half of the Bollinger Band range. The bands have begun to narrow, indicating a consolidation phase and lower near-term momentum. |
RSI (14)
Neutral
- The RSI currently stands at approximately 48.5.
- This places the indicator slightly below the neutral mark of 50.
- Following the significantly higher RSI values during the sharp price increase in June and July, momentum has continued to normalize.
Interpretation
The RSI currently indicates consolidation and balanced momentum.
MACD (12/26/9)
Negative
- The MACD line currently stands at approximately 0.47, below the signal line of approximately 0.64.
- The bearish crossover indicates weaker near-term momentum following the previous price increase.
- However, both the MACD and signal lines remain above the zero line. Therefore, the broader recovery trend has not been fully reversed to date.
Interpretation
The MACD currently signals fading near-term momentum and has not yet delivered a new positive signal.
Bollinger Bands
Neutral
- The upper Bollinger Band currently stands at approximately EUR 51.50.
- The lower band is at approximately EUR 46.06.
- The middle band is at approximately EUR 48.78.
- At a price of approximately EUR 47.45, the share is trading below the middle band but still above the lower band.
- Following the significant widening of the Bollinger Bands during the price increase in June and July, the bands have narrowed again.
Interpretation
The Bollinger Bands indicate decreasing volatility and an ongoing consolidation phase.
Opportunities
- The important support zone at EUR 46–47 remains intact to date.
- The broader recovery structure since the lows in spring has not been broken so far.
- The RSI is in neutral territory and does not signal pronounced negative momentum.
- Both MACD lines remain above the zero line despite the bearish crossover.
- A sustained breakout above the EUR 49.80–50.50 area could improve the technical picture and bring the recent highs back into focus.
Risks
- Near-term upward momentum has weakened following the previous price increase.
- The share is currently trading below the middle Bollinger Band.
- The MACD has formed a bearish crossover and has not yet delivered a new positive signal.
- The EUR 49.80–50.50 area continues to form a near-term resistance.
- A sustained decline below the support zone at EUR 46–47 would weaken the current recovery structure and increase the risk of a deeper correction.
Key takeaway: Bayer’s technical picture has shifted from positive momentum toward consolidation. The medium-term recovery structure remains intact; however, the MACD crossover and the decline from recent highs indicate weaker near-term momentum.
MUMAK.me Rating Phase 5: Neutral = 0 MUMAK
Bayer AG
What speaks for Bayer?
- The favorable U.S. Supreme Court decision significantly improves Bayer’s position in Roundup litigation.
- Crop Science shows stronger profitability as efficiency measures reduce costs.
- Nubeqa and Kerendia are developing into important growth drivers in the pharmaceutical business.
- The Apollo transaction strengthens Bayer’s capital structure and supports debt reduction.
- Bayer has returned to profitability in terms of reported net income.
- The long-term technical trend of the stock remains positive.
What speaks against Bayer?
- Net financial debt remains high.
- Settlement payments from litigation continue to weigh significantly on free cash flow.
- Xarelto and Eylea are under significant pressure due to patent expirations and competition.
- Group revenue growth remains comparatively low.
- Bayer’s profitability remains below that of many focused pharmaceutical companies.
What we are monitoring
- Legal developments: Further progress in the Roundup litigation and the impact of the Durnell decision.
- Operational performance: Growth of newer pharmaceutical products and the further development of profitability at Crop Science.
- Technical picture: The support zone at EUR 46–47 and the resistance area at EUR 49.80–50.50 remain key levels.
- Next quarterly report: Bayer will publish results for Q3 2026 on November 3, 2026. These will provide the next important update on operational performance and the full-year outlook.
Summary
Since our previous analysis, Bayer’s fundamental picture has remained largely unchanged. At the same time, developments in market sentiment and the technical picture provide additional reference points for the current assessment.
Operationally, Bayer remains on track following the Q2 2026 results. The company confirmed its currency-adjusted full-year outlook, while improved profitability at Crop Science provided support.
The legal environment has developed more constructively following the U.S. Supreme Court’s Durnell decision. The decision strengthens Bayer’s position in the Roundup litigation.
Market sentiment remains positive. At the same time, the technical picture has entered a neutral consolidation phase following the sharp price increase in June and July.
Overall, Bayer currently combines improved operational execution with progress in the legal environment. The upcoming Q3 results on November 3, 2026 will be an important reference point for whether the current operational performance continues.
Rating According to the MUMAK Method
| Category | Rating |
|---|---|
| Geopolitics | Positive |
| Industry | Positive |
| Fundamentals | Positive |
| News & Sentiment | Positive |
| Technical Analysis | Neutral |
